Financials data is unavailable for this security.
View more
Year on year Shionogi & Co Ltd was unable to grow net income despite reducing the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales). Net income shrank -12.40% from 184.97bn to 162.03bn despite revenues that were relatively flat.
| Gross margin | 85.70% |
|---|---|
| Net profit margin | 36.62% |
| Operating margin | 31.32% |
| Return on assets | 10.69% |
|---|---|
| Return on equity | 12.35% |
| Return on investment | 11.94% |
More ▼
Cash flow in JPYView more
In 2024, Shionogi & Co Ltd increased its cash reserves by 15.80%, or 48.87bn. The company earned 154.29bn from its operations for a Cash Flow Margin of 35.46%. In addition the company generated 5.92bn cash from investing, though they paid out 126.85bn more in financing than they received.
| Cash flow per share | 202.19 |
|---|---|
| Price/Cash flow per share | 10.59 |
| Book value per share | 1,519.70 |
|---|---|
| Tangible book value per share | 1,336.03 |
More ▼
Balance sheet in JPYView more
| Current ratio | 7.07 |
|---|---|
| Quick ratio | 6.48 |
| Total debt/total equity | 0.009 |
|---|---|
| Total debt/total capital | 0.0088 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share increased 18.52% while earnings per share excluding extraordinary items fell by -10.11%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.91% |
|---|---|
| Div growth rate (5 year) | 11.22% |
| Payout ratio (TTM) | 31.51% |
| EPS growth(5 years) | 5.13 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -26.83 |
More ▼
